ABVC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2023Q4

0.00

-100%

-0.500

-66.67%

Estimates Revision

Stock Price

Go Down

-33.74%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for ABVC Biopharma Inc (ABVC.O) is -0.48, compared to its 5-year average forward P/E of -4.74. For a more detailed relative valuation and DCF analysis to assess ABVC Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.74

Current PE

-0.48

Overvalued PE

2.48

Undervalued PE

-11.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

119.99

Current PS

12.37

Overvalued PS

408.09

Undervalued PS

-168.11

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABVC News & Events

Events Timeline

No data

News

9.0

2025-09-23Yahoo Finance

ABVC BioPharma, Inc. (ABVC) Sees 103% Increase in Assets, Preparing for Phase III Trials of Depression Treatments

9.5

2025-08-14NASDAQ.COM

Abvc BioPharma Doubles Assets in Q2

9.0

2024-12-19Newsfilter

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

People Also Watch

Frequently Asked Questions

What is ABVC Biopharma Inc (ABVC) stock price today?

The current price of ABVC is 2.18 USD — it has decreased -3.11 % in the last trading day.

What is ABVC Biopharma Inc (ABVC)'s business?

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.

What is the price predicton of ABVC Stock?

Wall Street analysts forecast ABVC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ABVC Biopharma Inc (ABVC)'s revenue for the last quarter?

ABVC Biopharma Inc revenue for the last quarter amounts to 795.95K USD, increased 104.47 % YoY.

What is ABVC Biopharma Inc (ABVC)'s earnings per share (EPS) for the last quarter?

ABVC Biopharma Inc. EPS for the last quarter amounts to -0.05 USD, increased 66.67 % YoY.

What changes have occurred in the market's expectations for ABVC Biopharma Inc (ABVC)'s fundamentals?

The market is revising No Change the revenue expectations for ABVC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.74%.

How many employees does ABVC Biopharma Inc (ABVC). have?

ABVC Biopharma Inc (ABVC) has 16 emplpoyees as of January 10 2026.

What is ABVC Biopharma Inc (ABVC) market cap?

Today ABVC has the market capitalization of 52.98M USD.